Association between the Germline MC1R Variants and Somatic BRAF/NRAS Mutations in Melanoma Tumors  by Scherer, Dominique et al.
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
We thank Dr Norito Ishii and Martin Ha¨nsel
for their help with the cyrosection assays. This
work was supported by Deutsche Forschungsge-
meinschaft, Cluster of Excellence ‘‘Inflammation
at Interfaces’’ (EXC 306/1).
Xinhua Yu1, Karoline Holdorf 2,
Brigitte Kasper1, Detlef Zillikens2,
Ralf J. Ludwig2 and Frank Petersen1
1Division of Biochemical Immunology,
Research Center Borstel, Borstel, Germany
and 2Department of Dermatology,
University of Lu¨beck, Lu¨beck, Germany
E-mail: fpeters@fz-borstel.de
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online
version of the paper at http://www.nature.com/jid
REFERENCES
Borrego L, Maynard B, Peterson EA et al. (1996)
Deposition of eosinophil granule proteins
precedes blister formation in bullous
pemphigoid. Comparison with neutrophil
and mast cell granule proteins. Am J Pathol
148:897–909
Chiriac MT, Roesler J, Sindrilaru A et al. (2007)
NADPH oxidase is required for neutrophil-
dependent autoantibody-induced tissue
damage. J Pathol 212:56–65
Gammon WR, Merritt CC, Lewis DM et al. (1982)
An in vitro model of immune complex-
mediated basement membrane zone sepa-
ration caused by pemphigoid antibodies,
leukocytes, and complement. J Invest Dermatol
78:285–90
Kasper B, Brandt E, Bulfone-Paus S et al. (2004)
Platelet factor 4 (PF-4)-induced neutrophil adhe-
sion is controlled by src-kinases, whereas PF-4-
mediated exocytosis requires the additional
activation of p38 MAP kinase and phosphatidyl-
inositol 3-kinase. Blood 103:1602–10
Kasperkiewicz M, Zillikens D (2007) The patho-
physiology of bullous pemphigoid. Clin Rev
Allergy Immunol 33:67–77
Li M, Wirthmueller U, Ravetch JV (1996) Recon-
stitution of human Fc gamma RIII cell type
specificity in transgenic mice. J Exp Med
183:1259–63
Liu Z, Giudice GJ, Zhou X et al. (1997) A
major role for neutrophils in experimental
bullous pemphigoid. J Clin Invest 100:
1256–63
Nimmerjahn F, Ravetch JV (2008) Fcgamma
receptors as regulators of immune responses.
Nat Rev Immunol 8:34–47
Sitaru C, Kromminga A, Hashimoto T et al.
(2002a) Autoantibodies to type VII collagen
mediate Fcgamma-dependent neutrophil ac-
tivation and induce dermal-epidermal se-
paration in cryosections of human skin. Am
J Pathol 161:301–11
Sitaru C, Schmidt E, Petermann S et al. (2002b)
Autoantibodies to bullous pemphigoid anti-
gen 180 induce dermal-epidermal separation
in cryosections of human skin. J Invest
Dermatol 118:664–71
Veri MC, Gorlatov S, Li H et al. (2007) Mono-
clonal antibodies capable of discriminating
the human inhibitory Fcgamma-receptor IIB
(CD32B) from the activating Fcgamma-
receptor IIA (CD32A): biochemical, bio-
logical and functional characterization.
Immunology 121:392–404
Zhao M, Trimbeger ME, Li N et al. (2006) Role of
FcRs in animal model of autoimmune bullous
pemphigoid. J Immunol 177:3398–405
Zone JJ, Taylor T, Hull C et al. (2007) IgE base-
ment membrane zone antibodies induce
eosinophil infiltration and histological blis-
ters in engrafted human skin on SCID mice.
J Invest Dermatol 127:1167–74
Association between the Germline MC1R Variants and
Somatic BRAF/NRAS Mutations in Melanoma Tumors
Journal of Investigative Dermatology (2010) 130, 2844–2848; doi:10.1038/jid.2010.242; published online 19 August 2010
TO THE EDITOR
Sporadic melanoma is associated with
high frequencies of somatic mutations
in BRAF, a serine–threonine kinase
acting in the mitogen-activated protein
(MAP) kinase pathway (Michaloglou
et al., 2008). Mutations in the gene
arise mainly in tumors that develop on
skin with intermittent sun exposure
(Dhomen and Marais, 2007). The most
frequent mutation in BRAF, an A-to-T
transversion at nucleotide 1799, results
in a valine to glutamic acid change at
codon 600 (Michaloglou et al., 2008).
BRAFV600E is intrinsically activated with
a several-hundred-fold increase in basal
kinase activity. The possible association
between the BRAFV600E mutation and
germline variants in the pigmentation-
related melanocortin receptor 1 (MC1R)
gene has been the focus of several
studies in recent years. MC1R is the
major contributor to pigmentation di-
versity in humans (Rees, 2003). The
receptor gene is highly polymorphic,
with more than 100 variants, many
being nonsynonymous (Garcia-Borron
et al., 2005). The importance of MC1R
is accentuated by the association of its
variants with skin pigmentation varia-
tion, skin cancer risk, and the pene-
trance of germline CDKN2A mutations
(Box et al., 2001; Sulem et al., 2007;
Scherer et al., 2009). So far, studies on
the association between germline
MC1R variants and frequency of som-
atic BRAF mutations in melanoma
tumors have produced inconsistent
results—some researchers have sug-
gested that the presence of MC1R
variants increases the frequency of BRAF
mutations; others found no association
(Landi et al., 2006; Fargnoli et al.,
2008; Hacker et al., 2009; Thomas
et al., 2010).
In the present study, we investi-
gated the correlation between MC1R
variants and the most common somatic
BRAF/NRAS mutations in 202 paraffin-
embedded primary melanoma tissues.
Mutations in BRAF and NRAS were
detected using single-strand conforma-
tion polymorphism and confirmed
by sequencing. The MC1R gene was
screened in three fragments by direct
sequencing. Out of all 202 tumors,
63 (31%) were superficial spreading
melanoma (SSM), 84 (42%) were
Abbreviations: ALM, acral lentigeous melanoma; LMM, lentigeous malignant melanoma; MAP, mitogen-
activated protein; NM, nodular melanoma; PKA, protein kinase A; RHC, red hair color; SSM, superficial
spreading melanoma
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nodular melanoma (NM), 20 (10%)
were lentigeous malignant melanoma
(LMM), 13 (6%) were acral lentigeous
melanoma (ALM), and 22 (11%) were
histologically not specified.
Screening for MC1R failed in 29
samples, for BRAF in 23 samples, and
for NRAS in 17 samples. Overall, 82.7%
of 173 genotyped tumors carried at
least one MC1R variant; 59.0% carried
one MC1R variant, 22.0% carried
two, and 1.7% carried three variants;
the red hair color (RHC) variants (D84E,
R142H, R151C, R160W, and D294H)
were observed in 57.2% of tumors
(Table 1).
Somatic mutations in the BRAF gene
were detected in 20.7% of screened
melanoma tumors (Table 1). All but one
of the mutations were observed at
the ‘‘hot spot’’ codon 600, with a
T1799A mutation (V600E) in 31 tumors
and a GT1798-99AA tandem mutation
(V600K) in five tumors. One tumor had
a T1792G mutation in codon 597,
resulting in a lysine-to-arginine switch.
In exon 2 of the NRAS gene, mutations
at codon 61 were detected in 23
(12.4%) tumors (Table 1). BRAF
and NRAS mutations were mutually
exclusive.
Of 132 tumors with at least one
MC1R variant, 22 (16.7%) carried a
somatic BRAF mutation. In contrast, of
24 samples with the MC1R consensus
sequence, 11 (45.8%) carried a BRAF
mutation. The odds ratio for the prob-
ability of the acquisition of somatic
BRAF mutations in tumors from indi-
viduals with the variant MC1R geno-
type was 0.24 (95% CI, 0.09–0.60;
P¼0.001; Table 2). The correlation
remained significant for RHC (OR,
0.23; 95% CI, 0.09–0.61; P¼0.002)
and non-RHC variants (OR, 0.25; 95%
CI, 0.08–0.79; P¼0.015) separately
(Table 2). In contrast, only 2 (8.0%) of
25 tumors with the MC1R consensus
sequence carried somatic NRAS muta-
tions, whereas of 127 tumors with
MC1R variants 17 (13.4%) revealed an
NRAS mutation (OR, 1.78; 95% CI,
0.38–8.23; P¼ 0.46; Table 2).
Stratification of the data according to
histological melanoma subtype showed
that the observed correlation between
MC1R variants and oncogenic BRAF
mutations was restricted to the subset
of 61 NM. Of 47 NM samples that
had at least one MC1R variant, only
six (12.8%) tumors revealed a BRAF
mutation compared with eight (57.1%)
in which no MC1R variant was
present (OR, 0.11; 95% CI, 0.03–0.43;
Po0.001; Table 2). This significant
observation held for RHC variants as
well (OR, 0.17; 95% CI, 0.04–0.66;
P¼0.008; Table 2). In contrast, for
53 analyzed SSM tumors we did not
observe this correlation between MC1R
variants and BRAF mutations (OR, 1.65;
95% CI, 0.17–16.07; P¼0.67). Owing
Table 1. MC1R variant and BRAF/NRAS mutation frequencies in primary melanoma tumors according to
histological melanoma subtype
Histotype
Gene All SSM NM LLM ALM NOS
MC1R
X1 variant 82.7% (143) 35.0% (50) 37.0% (53) 9.8% (14) 6.3% (9) 11.9% (17)
1 variant 59.0% (102) 36.3% (37) 37.2% (38) 8.8% (9) 5.9% (6) 11.8% (12)
2 variants 22.0% (38) 28.9% (11) 39.5% (15) 10.5% (4) 7.9% (3) 13.2% (5)
3 variants 1.7% (3) 66.6% (2) — 33.4% (1) — —
RHC variants 57.2% (99) 34.3% (34) 38.4% (38) 10.1% (10) 7.1% (7) 10.1% (10)
non-RHC variants 25.5% (44) 36.4% (16) 34.1% (15) 9.1% (4) 4.5% (2) 15.9% (7)
BRAF
Total 20.7% (37) 43.2% (16) 43.2% (16) 2.7% (1) 2.7% (1) 8.2% (3)
V600E 17.3% (31) 41.9% (13) 48.4% (15) — 3.2% (1) 6.5% (2)
V600K 3.0% (5) 40.0% (2) 20.0% (1) 20.0% (1) — 20.0% (1)
L597R o1% (1) 100.0% (1) — — — —
NRAS
Total 12.4% (23) 17.4% (4) 60.9% (14) 4.3% (1) 4.3% (1) 13.1% (3)
Q61K 9.1% (16) 25.0% (4) 50.0% (8) 6.3% (1) 6.3% (1) 12.5% (2)
Q61R 3.2% (5) — 80.0% (4) — — 20.0% (1)
Q61L 1.1% (2) — 100.0% (2) — — —
Abbreviations: ALM, acral lentigeous melanoma; LMM, lentigeous malignant melanoma; MC1R, melanocortin receptor 1; mut, mutated; NM, nodular
melanoma; NOS, not specified; RHC, red hair color variant; SSM, superficial spreading melanoma; wt, wild type.
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Table 2. Distribution of somatic mutations in the BRAF (a) and NRAS (b) genes in MC1R carriers and noncarriers
according to histological melanoma subtype
Histotype MC1R consensus MC1R carrier RHC1 Non-RHC
(a)
All
BRAF
wt 54.2% (13) 83.3% (110) 83.7% (77) 82.5% (33)
mut 45.8% (11) 16.7% (22) 16.3% (15) 17.5% (7)
OR (95% CI) ref 0.24 (0.09–0.60) 0.23 (0.09–0.61) 0.25 (0.08–0.79)
P 0.001 0.002 0.015
SSM
BRAF
wt 80.0% (4) 70.8% (34) 75.8% (25) 60.0% (9)
mut 20.0% (1) 29.2% (14) 24.2% (8) 40.0% (6)
OR (95% CI) ref 1.65 (0.17–16.07) 1.28 (0.12–13.17) 2.67 (0.24–30.07)
P 0.67 0.84 0.42
NM
BRAF
wt 42.9% (6) 87.2% (41) 81.8% (27) 100.0% (14)
mut 57.1% (8) 12.8% (6) 18.2% (6) 0
OR (95% CI) ref 0.11 (0.03–0.43) 0.17 (0.04–0.66) NA
P o0.001 0.008
LMM
BRAF
wt 100.0% (1) 92.3% (12) 90.0% (9) 100.0% (3)
mut 0 7.7% (1) 10.0% (1) 0
OR (95% CI) ref NA NA NA
P
ALM
BRAF
wt 66.7% (2) 100.0% (9) 100.0% (7) 100.0% (2)
mut 33.3 (1) 0 0 0
OR (95% CI) ref NA NA NA
P
All2
BRAF
wt 50.0% (11) 80.7% (92) 81.5% (66) 78.8% (26)
mut 50.0% (11) 19.3% (22) 18.5% (15) 21.2% (7)
OR (95% CI) ref 0.24 (0.09–0.62) 0.23 (0.08–0.62) 0.27 (0.08–0.88
P 0.002 0.003 0.026
All3
BRAF
wt 55.0% (11) 80.6% (87) 80.3% (61) 81.3% (26)
Mut 45.0% (9) 19.4% (21) 19.7% (15) 18.7% (6)
Table 2 continued on the following page
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to the low numbers of ALM and LMM,
no separate analysis was performed for
those subtypes.
The cross-talk between the pigmen-
tation and the MAP kinase pathways
is well known; however, the effect of
MC1R variants on somatic mutations
has remained unresolved (Dhomen and
Marais, 2007; Fargnoli et al., 2008;
Michaloglou et al., 2008; Hacker et al.,
2009). We observed that the frequency
of somatic BRAF mutations was signifi-
cantly lower in carriers of MC1R
variants than in noncarriers. However,
the observed correlation was restricted
to NM, which is the second most
common subtype of melanoma. NM
lacks the radial growth phase and is
generally detected in its later stages.
Involvement of distinct pathways in the
development of SSM and NM is in-
dicated by differences in gene expres-
sion patterns (Jaeger et al., 2007;
Warycha et al., 2008).
One plausible explanation for the
observed correlation between germline
MC1R variants and somatic BRAF
mutations in our study could be that
in normal melanocytes NRAS signaling
is usually directed through BRAF,
which is a stronger activator of the
downstream signaling than CRAF
(Dumaz et al., 2006). Mutated NRAS
seems to use intrinsically weak CRAF
instead of BRAF for downstream signal-
ing (Dumaz et al., 2006). In normal
melanocytes, CRAF is, in general,
inactivated through protein kinase A
(PKA), which is a downstream effecter
of elevated cAMP levels due to signal-
ing from MC1R ligand binding (Micha-
loglou et al., 2008). Most of the loss-of-
function MC1R variants are associated
with decreased cAMP levels and con-
sequently reduced PKA function. It is
reasonable to infer that the presence of
MC1R variants results in diminished
suppression of CRAF facilitating signal-
ing by mutant NRAS. The presence of
MC1R variants might contribute to the
selection of clones with mutant NRAS.
Our findings in this study are in accord
with those observations. Two previous
studies, however, showed increased
frequency of BRAF mutations in the
carriers of MC1R variants (Landi et al.,
2006; Fargnoli et al., 2008); two other
studies found no association (Hacker
et al., 2009; Thomas et al., 2010).
Further studies with larger numbers of
tumor samples are imperative to vali-
date the true correlation between the
germline MC1R variants and somatic
oncogenic mutations in melanoma,
with an emphasis on separation of
tumor subtypes.
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Table 2. Continued
Histotype MC1R consensus MC1R carrier RHC1 Non-RHC
OR (95% CI) ref 0.30 (0.11–0.80) 0.24 (0.08–0.66) 0.25 (0.08–0.81)
P 0.013 0.020 0.042
(b)
All
NRAS
wt 92.0% (23) 86.6% (110) 88.5% (77) 82.5% (33)
mut 8.0% (2) 13.4% (17) 11.5% (10) 17.5% (7)
OR (95% CI) ref 1.78 (0.38–8.23) 1.49 (0.31–7.31) 2.44 (0.46–12.82)
P 0.46 0.62 0.28
All4
NRAS
wt 86.7% (13) 84.3% (91) 86.5% (64) 79.4% (27)
mut 13.3% (2) 15.7% (17) 13.5% (10) 20.6% (7)
OR (95% CI) ref 1.21 (0.25–5.87) 1.02 (0.20–5.19) 1.69 (0.31–9.27)
P 0.81 0.99 0.55
Abbreviations: ALM, acral lentigeous melanoma; CI, confidence interval; LMM, lentigeous malignant melanoma; MC1R, melanocortin receptor 1; mut,
mutated; NA, not analyzed; NM, nodular melanoma; OR, odds ratio; RHC, red hair color variant; SSM, superficial spreading melanoma; wt, wild type.
1Two individuals were homozygous for the R151C variants and two were homozygous for the R160W variant. All other individuals were heterozygous for
RHC variants.
2Individuals whose tumors were positive for NRAS mutations were excluded.
3Individuals whose tumors were either of the ALM type or not specified were excluded.
4Individuals whose tumors were positive for BRAF mutations were excluded.
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Vitamin D Synthesis May Be Independent of Skin
Pigmentation Only with UV of Short Wavelength
Journal of Investigative Dermatology (2010) 130, 2848–2850; doi:10.1038/jid.2010.228; published online 23 September 2010
TO THE EDITOR
Bogh et al. (2010) found that accumu-
lation of 25-hydroxyvitamin D is not
affected by skin pigmentation. I would
like to point to a possible explanation to
the seeming contradiction between
their results and those of many observa-
tional investigations, which have found
that vitamin D status is better and
vitamin D production proceeds more
readily in people with fairer skin.
Bogh et al. (2010) measured the
increase of plasma 25-hydroxyvitamin
D caused by unfiltered radiation from
Philips TL12 lamps containing very
shortwave components, including a
significant component at wavelengths
o290 nm. Such radiation is efficiently
absorbed by 7-dehydrocholesterol (7-
DHC, provitamin D3) in the upper
epidermis, outside the most pigmented
skin layer. Daylight, on the other hand,
contains effectively no radiation below
290 nm. The transmission of the stratum
corneum can exceed 90% at 300 nm
and increases with wavelength (Philp
and Allcock, 1989), so some previtamin
D3-producing radiation, even that of
very short wavelength, can reach the
outer epidermal layers. The stratum
granulosum does not contain much
melanin, but some provitamin D3,
which can therefore be converted to
previtamin D, even in heavily pigmen-
ted individuals.
Compared with light-skinned people
living at the same latitude, dark-skinned
persons generally have lower vitamin D
status. The spring rise in vitamin D
status is also lower in dark-skinned
people (Harris and Dawson-Hughes,
1998). Exposure of isolated human skin
to summer sunlight and exposure
in vivo of humans to sunbeds simulat-
ing sunlight showed that Caucasian skin
is more efficient at forming previtamin
D3 than is African American skin
(Armas et al., 2007; Chen et al., 2007).
The radiation spectra of the lamps
used by Bogh et al. (2010) and Armas
et al. (2007) are shown in Figure 1,
together with a daylight spectrum cal-
culated for the conditions of Chen et al.
(2007) in their daylight experiment. It
can be seen that Bogh et al. (2010),
who did not find any effect of pigmen-
tation, used treatments with a larger
proportion of short-wave UV radiation
than did Armas et al. (2007) and
Chen et al. (2007), who found such an
effect.
Figure 2 shows an absorption spec-
trum (in relative units) for the previta-
min D3 precursor, 7-DHC, together with
transmission spectra for human stratum
corneum and epidermis redrawn from
Bruls et al. (1984). 7-DHC occurs
throughout the epidermis (Holick et al.
(1980) found 58, 393, and 303 ng cm2
in the stratum corneumþ granulosum,
stratum spinosum, and stratum basale,
respectively). Short-wavelength radia-
tion does not penetrate far into the
epidermis, but can efficiently convert
the 7-DHC in the superficial layers, asAbbreviation: 7-DHC, 7-dehydrocholesterol (provitamin D3)
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Vitamin D and Skin Color
